What Is Carfilzomib? Definition and What Research Reports

Definition

Carfilzomib is a synthetic, peptide-based small molecule — specifically a tetrapeptide epoxyketone — that binds covalently and essentially irreversibly to the chymotrypsin-like (β5) catalytic site of the 20S proteasome, the cellular machine that degrades tagged proteins. Blocking that site causes polyubiquitinated proteins to accumulate, which is toxic to plasma cells that carry a heavy secretory protein load. Clinically it is an intravenous prescription anticancer agent used in relapsed or refractory multiple myeloma, marketed under the brand name Kyprolis. In glossaries it often sits under "peptides" because of its four-residue peptide backbone, but it is a regulated chemotherapeutic drug rather than a research-market peptide, and it is administered only in supervised oncology settings.

What Class of Molecule Is Carfilzomib?

Structurally, carfilzomib consists of a short peptide chain capped by an epoxyketone "warhead." That warhead reacts with the catalytic N-terminal threonine of the proteasome's β5 subunit to form a stable morpholino adduct — a covalent bond that does not readily reverse. This distinguishes it from bortezomib, a boronic-acid dipeptide whose proteasome binding is slowly reversible; the two drugs were compared head to head in a randomised phase 3 setting.

• Chemical class: tetrapeptide epoxyketone; a peptidomimetic derived from the natural product epoxomicin, originally isolated from actinomycete bacteria.
• Source: fully chemically synthesised for pharmaceutical use; it is not extracted from tissue and is not an endogenous human peptide.
• Molecular target: the 20S proteasome, with dominant activity at the β5 (chymotrypsin-like) subunit and additional activity at β2, a selectivity profile that researchers examined directly in a 2025 mechanistic study of carfilzomib-specific β5/β2 inhibition (PMID 40894880).
• Route in trials: intravenous infusion, dosed by body surface area (mg/m²) in the registration studies described below.

How the Term Is Used in Peptide Research

Carfilzomib appears in peptide-related literature in three distinct ways. First, as a textbook example of a peptidomimetic drug: a molecule whose backbone is peptide-like but whose pharmacology depends on a non-peptide reactive group. Second, as a tool compound in cell biology, where proteasome inhibition is used to probe protein homeostasis, autophagic flux, the unfolded protein response and ubiquitin signalling. Third, as a subject of resistance research; a 2025 comparative metabolomic analysis profiled metabolic differences associated with carfilzomib resistance in multiple myeloma models (PMID 41102430). None of these usages describe a consumer or wellness context — the compound is a cytotoxic prescription drug.

What the Clinical Literature Reports

Carfilzomib's evidence base rests on large randomised phase 3 trials in relapsed or refractory multiple myeloma, in which researchers compared carfilzomib-containing regimens with control regimens and measured progression-free survival as the primary endpoint.

All four were open-label randomised trials in patients whose myeloma had relapsed after prior therapy; none evaluated carfilzomib in healthy participants or for any non-oncology indication.

Cardiac, Renal and Vascular Events: What Studies Report

Safety signals are a prominent part of the carfilzomib literature. In the ENDEAVOR comparison, researchers reported higher rates of hypertension and dyspnoea in the carfilzomib group than in the bortezomib group (PMID 26671818). A 2017 analysis in Blood Advances examined cardiac and renal complications among patients with multiple myeloma treated with carfilzomib and characterised their frequency, timing and clinical features (PMID 29296960).

A separate and well-documented signal is thrombotic microangiopathy (TMA), a syndrome of microvascular clotting with haemolysis and organ injury. Two published case reports described carfilzomib-associated thrombotic microangiopathy and its clinical course (PMID 39390755), and a 2025 case report described complement genetic alterations in a patient who developed carfilzomib-associated TMA and was treated with eculizumab (PMID 40895697). A 2022 case-based review focused specifically on proposed pathogenic mechanisms of carfilzomib-induced thrombotic microangiopathy (PMID 35837078).

Preclinical and Mechanistic Reports

Laboratory work has concentrated on why carfilzomib affects the heart. A 2025 iScience study reported that carfilzomib-specific inhibition of the proteasome β5 and β2 activities drove cardiotoxicity through remodelling of protein homeostasis and of the renin-angiotensin system (PMID 40894880). A separate study reported that carfilzomib induced cardiotoxicity by blocking autophagic flux through cGAS-STING signalling (PMID 42352320). Not all preclinical findings describe harm: a 2023 mouse study reported that carfilzomib mitigated lipopolysaccharide/D-galactosamine/dimethylsulfoxide-induced acute liver failure (PMID 38002097). Findings in rodents and cell systems do not establish the same effects in humans.

Regulatory and Research Context

Carfilzomib is an approved prescription drug for relapsed or refractory multiple myeloma and is supplied as a sterile injectable for hospital and clinic administration. It is not an over-the-counter supplement, not a compounded wellness peptide, and not a substance that appears in legitimate consumer channels. Analytical-grade material used in cell culture is labelled for laboratory research use only. Because the drug is cytotoxic and has documented cardiovascular and renal signals, its published use is confined to oncology protocols with monitoring.

Common Points of Confusion

• "Peptide" does not mean benign. Carfilzomib's peptide backbone is a delivery scaffold for a reactive epoxyketone; it does not behave like a signalling peptide.
• It is not interchangeable with bortezomib. The two proteasome inhibitors differ chemically and were directly compared in a randomised trial with distinct efficacy and toxicity profiles (PMID 26671818).
• Doses in the literature are protocol-specific. Figures such as 27 mg/m² or 56 mg/m² describe what a given trial administered under supervision (PMID 25482145, PMID 32682484) and are reported here as study details only.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medical condition, medication or treatment.

References

• Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma (The New England Journal of Medicine, 2015)
• Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) (The Lancet Oncology, 2016)
• Cardiac and renal complications of carfilzomib in patients with multiple myeloma (Blood Advances, 2017)
• Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR) (Lancet, 2020)
• Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA) (Lancet, 2021)
• Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis (Journal of Medical Cases, 2022)
• Carfilzomib Mitigates Lipopolysaccharide/D-Galactosamine/Dimethylsulfoxide-Induced Acute Liver Failure in Mice (Biomedicines, 2023)
• Carfilzomib-Induced Thrombotic Microangiopathy—Two Case Reports (Cancer Reports, 2024)
• Carfilzomib-specific proteasome β5/β2 inhibition drives cardiotoxicity via remodeling of protein homeostasis and the renin-angiotensin-system (iScience, 2025)
• Carfilzomib-Associated Thrombotic Microangiopathy in a Multiple Myeloma Patient: Complement Genetic Alterations Impact and Eculizumab Therapy (Cureus, 2025)
• Carfilzomib resistance in multiple myeloma: A comparative metabolomic analysis (Journal of Applied Genetics, 2025)
• Carfilzomib Induces Cardiotoxicity by Blocking Autophagic Flux Through the cGAS-STING Signaling Pathway (Biomolecules, 2026)